A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer

Trial Profile

A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Panitumumab (Primary) ; Cetuximab
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ASPECCT
  • Sponsors Amgen
  • Most Recent Events

    • 29 Jun 2017 Results published in an Amgen media release.
    • 29 Jun 2017 According to an Amgen media release, the FDA has approved Vectibix (panitumumab) for the treatment of wild-type RAS metastatic colorectal cancer. The full approval for Vectibix as a treatment for patients with wild-type KRAS mCRC was based on results from the Phase 3 PRIME and ASPECCT trials. The approval of a refined indication for the treatment of patients with wild-type RAS mCRC was based on a retrospective analysis from this study and prospective, pre-defined analyses from the 0007 study.
    • 06 Jun 2017 Results assessing Profiling circulating tumor (ct)DNA mutations after panitumumab treatment presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top